Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for SynCore Biotechnology Co., Ltd. (4192:TWSE), powered by AI.
SynCore Biotechnology Co., Ltd. is currently trading at $20.55. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for SynCore Biotechnology Co., Ltd. on Alpha Lenz.
View SynCore Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.
“SynCore Biotechnology Co., Ltd.'s ROE is -16.9%. Explore profitability and growth together.”
Ask for details →SynCore Biotechnology Co., Ltd. is a biopharmaceutical company based in Yilan, Taiwan, focused on the research, development, production, and commercialization of therapeutic drugs. Established in 2008 by Chih Wen Li, the company operates primarily within the health technology sector, with a specialization in major pharmaceuticals and biotechnology services. SynCore is engaged in a range of activities including novel drug discovery, food advisory, medicine inspection, and intellectual property management. Its portfolio features products such as SB03 Veregen, alongside the active development and clinical trial evaluation of anticancer therapeutics like SB01 in both injectable and oral formulations. With a workforce of approximately 40 employees, SynCore Biotechnology Co., Ltd. plays a significant role in Taiwan’s biotechnology and medical research industry, contributing to advancements in cancer treatment and allied pharmaceutical fields. The company distributes its products mainly within the domestic market, reinforcing its position in the Taiwanese life sciences landscape.
“SynCore Biotechnology Co., Ltd.'s ROE is -16.9%. Explore profitability and growth together.”
Ask for details →SynCore Biotechnology Co., Ltd. (ticker: 4192) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 40 employees.
The current price is 20.55 with a P/E ratio of -x and P/B of -x.
ROE is -16.94% and operating margin is -174.52%. Annual revenue is $27M.